Tawee Tanvetyanon

Oncology

4101 Jim Walter Blvd
Tampa, FL 33607

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 105 publications

Mesothelioma: Pleural, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.

Mesothelioma: Pleural, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: August 17, 2026

Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 09, 2026

HER-2 Altered Early-Stage Non-Small Cell Lung Cancer Had Better Survival than Triple-Negative Disease.

HER-2 Altered Early-Stage Non-Small Cell Lung Cancer Had Better Survival than Triple-Negative Disease.

Journal: Journal of clinical medicine

Published: February 19, 2026

Timing of Durvalumab Consolidation and Survival in Non-Small Cell Lung Cancer: A Population-Based Analysis.

Timing of Durvalumab Consolidation and Survival in Non-Small Cell Lung Cancer: A Population-Based Analysis.

Journal: JCO oncology practice

Published: December 10, 2025

Comparison of subcutaneous checkpoint inhibitor immunotherapeutic agents.

Comparison of subcutaneous checkpoint inhibitor immunotherapeutic agents.

Journal: Journal of thoracic disease

Published: September 21, 2025

Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab Use.

Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab Use.

Journal: Clinical lung cancer

Published: September 21, 2025

NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025.

NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: September 10, 2025

Relationship between PD-L1 Expression and Outcomes of Salvage Treatment Following Durvalumab Consolidation.

Relationship between PD-L1 Expression and Outcomes of Salvage Treatment Following Durvalumab Consolidation.

Journal: Clinical lung cancer

Published: July 31, 2025

Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: June 11, 2025

Timeliness of Newer Targeted Therapy and Survival in Lung Cancer: A Population-Based Analysis.

Timeliness of Newer Targeted Therapy and Survival in Lung Cancer: A Population-Based Analysis.

Journal: JCO oncology practice

Published: June 05, 2025

A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).

A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 08, 2024

Association between Infection and Calculated Globulin Level among Patients with Thymic Epithelial Tumor.

Association between Infection and Calculated Globulin Level among Patients with Thymic Epithelial Tumor.

Journal: Journal of clinical medicine

Published: August 01, 2024

Showing 1-12 of 105

Last Updated: 09/26/2026